Supplementary Information

[Ru^{IV}(F₂₀-TPP)Cl₂] Efficiently Catalysed Inter- and Intra-Molecular Nitrene Insertion into sp³ C-H Bonds of Hydrocarbons Using Phosphoryl Azides as Nitrene Source

Wenbo Xiao,^a Jinhu Wei,^a Cong-Ying Zhou,^{*,a,b} Chi-Ming Che ^{*,a,b}

^a Department of Chemistry, State Key Laboratory of Synthetic Chemistry, and Open Laboratory of Chemical Biology of the Institute of Molecular Technology for Drug Discovery and Synthesis, The University of Hong Kong, Pokfulam Road, Hong Kong, China.
^b HKU Shenzhen Institute of Research & Innovation ,Shenzhen, China
Fax: (852) 2857-1586; Tel: (852) 2859-2154; E-mail: cmche@hku.hk, cyzhou@hku.hk

I. General Information1
II. Synthesis of Ruthenium(IV) Porphyrin Catalysts1
III. Synthesis of Phosphoryl Azides
IV. General Procedure for the Reactions in Table 14
V. General Procedure for the Reactions in Table 25
VI. General Procedure for the [Ru ^{IV} (F ₂₀ -TPP)Cl ₂]-catalysed Intermolecular C-H
Amination of Hydrocarbons with Phosphoryl Azide (Table 3)5
VII. General Procedure for the $[Ru^{IV}(F_{20}-TPP)Cl_2]$ -catalysed Intramolecular
C-H Amination of Phosphorazidates (Scheme 1)5
VIII. Procedure for the Study of Deuterium Kinetic Isotope Effects
IX. Characterizations of Products7
NMR Spectra15

I. General Information

Unless otherwise stated, all reactions were performed under argon atmosphere. DPPA was purchased from Acros. [Rh₂(esp)₂] was purchased from Sigma-Aldrich. Molecular sieves were dried at 400 $^{\circ}$ C for 3 h prior to use. All solvents and hydrocarbons were purified by distillation using standard methods. Metal porphyrin catalysts and other organic azides were synthesized according to previously reported methods. All ¹H NMR and ¹³C NMR spectra were recorded on Bruker AV300, AV400 and AV500 NMR spectrometers with tetramethylsilane (TMS) as internal reference. ³¹P NMR spectra were recorded on Bruker AV400 NMR spectrometer with 85% H₃PO₄ as external reference. Mass spectra were recorded on Finnigan MAT 95 mass spectrometer. ESI mass spectra were obtained on a Waters Micromess Q-Tof Premier quadrupole time-of-flight tandem mass spectrometer. *Caution!* Organic azides are potentially explosive and should be handled with great care.

II. Synthesis of Ruthenium(IV) Porphyrin Catalysts

Ruthenium(IV) porphyrin catalysts were synthesized according to the following references.

[Ru ^{IV} (TDCPP)Cl ₂]	JL. Zhang and CM. Che, Chem. Eur. J., 2005, 11, 3899.
[Ru ^{IV} (TPP)Cl ₂]	WH., Leung, T. S. M. Hun, Hw. Hou, KY. Wong, J. Chem.
	Soc., Dalton Trans. 1997, 237.
[Ru ^{IV} (F ₂₀ -TPP)Cl ₂]	C. Wang, K. V. Shalyaev, M. Bonchio, T. Carofiglio and J. T.
	Groves, Inorg. Chem., 2006, 45, 4769-4782.

Synthesis of [Ru^{IV}(F₂₀-TPP)Cl₂]

$$[Ru^{II}(F_{20}\text{-}TPP)(CO)] \xrightarrow{m\text{-}CPBA} [Ru^{VI}(F_{20}\text{-}TPP)(O)_2] \xrightarrow{HCI} [Ru^{IV}(F_{20}\text{-}TPP)CI_2]$$

To a solution of $[Ru^{II}(F_{20}-TPP)(CO)]$ (66 mg, 0.06 mmol) in 20 mL of dichloromethane was added 202 mg of m-CPBA (77%, 0.9 mmol). The reaction mixture was stirred for 20 min until UV spectrum indicated complete consumption of $[Ru^{II}(F_{20}-TPP)(CO)]$. Then the reaction mixture was flushed through a short alumina column and concentrated by rotary evaporator to give crude $[Ru^{VI}(F_{20}-TPP)(O)_2]$ for the next step.

[Ru^{VI}(F₂₀-TPP)(O)₂] was dissolved in 100 mL of anhydrous dichloromethane. Anhydrous HCl was bubbled through the solution for 1 h. After 12 h, the solvent was removed. The obtained solid was washed with diethyl ether to give [Ru^{IV}(F₂₀-TPP)Cl₂] (21 mg) in total yield of 30% . ¹H NMR (CDCl₃, 400MHz): δ -51.1(br, 8H); ¹⁹F NMR (CDCl₃, 376MHz): δ -129.7, -148.9, -158.9; UV-Vis (CH₂Cl₂) λ_{max} /nm (log ε): 406 (5.01), 507(3.91); LRMS(ESI) m/z Calcd. For C₄₄H₈Cl₂F₂₀N₄Ru [M]⁺ 1143.9, found 1144.0; [M-Cl]⁺ 1108.9, found 1109.0; [M-2Cl]⁺ 1073.9, found 1074.0.

III. Synthesis of Phosphoryl Azides

Bis(2,2,2-trichloroethyl) phosphorazidate was synthesized according to reported method. (W. Xiao, C.-Y. Zhou and C.-M. Che, *Chem. Commun.*, 2012, **48**, 5871-5873)

The general procedure for the synthesis of intramolecular substrates 4a, 4b, 4c and 4d

$$\begin{array}{c|c} POCI_{3} \xrightarrow{PhOH} & PhO-\stackrel{O}{P}-CI & \xrightarrow{ROH} & PhO-\stackrel{O}{P}-OR & \xrightarrow{NaN_{3}} & PhO-\stackrel{O}{P}-OR \\ \hline CI & t_{3}N, Et_{2}O & CI & CI & Acetone & N_{3} \\ \hline 1) & 2) & 3) \end{array}$$

Step 1)

To a dry flask equipped with an argon inlet and an addition funnel was added phosphorus oxychloride (3.067 g, 20 mmol) and 60 mL of anhydrous diethyl ether under argon atmosphere. The solution was cooled down to -78°C in an acetone-liquid nitrogen bath with stirring. A solution of phenol (1.882 g, 20 mmol) and triethylamine (2.226 g, 22 mmol) in 20 mL of diethyl ether was added dropwise within 1 hour. After the complete addition of phenol and triethylamine, the reaction mixture was slowly warmed up to room temperature and stirred for 12 hours. Subsequently, the reaction mixture was filtered to remove the white solid. The filtrate was concentrated by a rotary evaporator to give the light yellow liquid product in 95% yield. The product was directly used for the next step without further purification. Step 2)

A dry flask equipped with an argon inlet and an addition funnel was charged with phenyl phosphorodichloridate (422 mg, 2 mmol) and 5 mL of anhydrous diethyl ether under argon

atmosphere. The solution was cooled down to -78° C in an acetone-liquid nitrogen bath with stirring. A solution of alcohol (2 mmol) and triethylamine (223 mg, 2.2 mmol) in 10 mL of diethyl ether was added dropwise within 0.5 hour. After the complete addition of alcohol and triethylamine, the reaction mixture was slowly warmed up to room temperature and stirred for 12 ~ 24 hours. When ³¹P NMR indicated the complete consumption of phenyl phosphorodichloridate, the reaction mixture was filtered. The filtrate was concentrated by a rotary evaporator to give the corresponding product in high yield. The product was directly used for the next step without further purification.

Step 3)

The phosphorochloridate (3 mmol) was dissolved in 20 mL of acetone. Sodium azide (3.3 mmol) was added to the solution. The reaction mixture was stirred in darkness for several hours until the phosphorochloridate was completely consumed. The reaction mixture was filtered to remove the precipitated white solid. The filtrate was concentrated and purified by column chromatography (hexane : DCM = 3 : 1) to give the product.

Phenyl (3-phenylpropyl) phosphorazidate 4a

¹H NMR (CDCl₃, 400MHz): δ 7.40-7.15 (m, 10H), 4.24 (dd, 2H, J = 13.8, 6.4Hz), 2.73 (t, 2H, J = 7.6Hz), 2.09-2.02 (m, 2H); ¹³C NMR (CDCl₃, 125MHz): δ 150.0(d, J = 7.5Hz), 140.5, 130.1, 128.7, 128.6, 126.3, 126.0, 120.3 (d, J = 4.7Hz), 68.8 (d, J = 6.8Hz), 31.7 (d, J = 6.9Hz), 31.5; ³¹P NMR (CDCl₃,162MHz): δ -5.2.

HRMS(ESI) m/z Calcd for $C_{15}H_{17}N_3O_3P [M+H]^+ 318.1008$, found 317.9998.

Butyl phenyl phosphorazidate 4b

¹H NMR (CDCl₃, 500MHz): δ 7.38 (t, 2H, J = 7.8Hz), 7.26-7.22 (m, 3H), 4.27-4.22 (m, 2H), 1.76-1.69 (m, 2H), 1.44-1.40 (m, 2H), 0.94 (t, 3H, J = 7.4Hz); ¹³C NMR (CDCl₃,125MHz): δ

150.0 (d, J = 7.6Hz), 130.0, 125.8, 120.2 (d, J = 4.8Hz), 69.4 (d, J = 6.9Hz), 32.1 (d, J = 6.8Hz), 18.6, 13.5; ³¹P NMR (CDCl₃, 162MHz): δ -5.2.

HRMS(ESI) m/z Calcd for $C_{10}H_{15}N_3O_3P [M+H]^+ 256.0851$, found 256.0869.

Isobutyl phenyl phosphorazidate 4c



¹H NMR (CDCl₃, 400MHz): δ 7.37 (t, 2H, J = 7.7Hz), 7.26-7.21 (m, 3H), 4.00 (t, 2H, J = 6.8Hz), 2.07-1.97 (m, 1H), 0.97 (s, 3H), 0.96 (s, 3H); ¹³C NMR (CDCl₃, 125MHz): δ 150.1 (d, J = 7.4Hz), 130.0, 125.9, 120.3 (d, J = 4.7Hz), 75.4 (d, J = 7.2Hz), 29.1 (d, J = 7.1Hz), 18.6; ³¹P NMR (CDCl₃, 162MHz): δ -5.3.

HRMS(ESI) m/z Calcd for $C_{10}H_{15}N_3O_3P [M+H]^+ 256.0851$, found 256.0848.

Phenethyl phenyl phosphorazidate 4d



¹H NMR (CDCl₃, 400MHz): δ 7.36-7.14 (m, 10H), 4.42 (dd, 2H, J = 14.7, 7.2Hz), 3.04 (t, J = 6.9Hz); ¹³C NMR (CDCl₃, 100MHz): δ 149.9(d, J = 7.8Hz), 136.4, 130.0, 129.1, 128.7, 127.0, 125.9, 120.2 (d, J = 4.7Hz), 69.7 (d, J = 6.9Hz), 36.6 (d, J = 6.9Hz); ³¹P NMR (CDCl₃, 162MHz): δ -5.4.

HRMS(ESI) m/z Calcd for $C_{14}H_{15}N_3O_3P [M+H]^+ 304.0851$, found 304.0855.

IV. General Procedure for the Reactions in Table 1

To an oven-dried Schlenk flask with a rubber seal was added the corresponding nitrene source (0.1 mmol, 1 equiv.), $Ru^{IV}(TDCPP)Cl_2$ (2 mol %) and 50 mg of 4Å molecular sieve. The flask was evacuated and backfilled with argon three times. Then freshly distilled cyclohexane (2 mmol, 20 equiv.) and 1.5 mL of DCE were added via syringe. The mixture

was stirred at reflux for 12 h. Subsequently, the reaction mixture was allowed to cool down to room temperature and directly purified on a silica gel column with DCM/acetone (50:1, v/v) as eluent to give the pure product.

V. General Procedure for the Reactions in Table 2

An oven-dried Schlenk flask with a rubber seal was charged with bis(2,2,2-trichloroethyl) phosphorazidate (0.1 mmol, 1 equiv.), catalyst (2 mol %) and 50 mg of 4Å molecular sieve. The flask was evacuated and backfilled with argon three times. Then freshly distilled cyclohexane (2 mmol, 20 equiv.) and 1.5 mL of DCE were added via syringe. The mixture was stirred at reflux for 12h. Subsequently, the reaction mixture was allowed to cool down to room temperature and directly purified on a silica gel column with DCM/acetone (50:1, v/v) as eluent to give the pure product.

VI. General Procedure for the [Ru^{IV}(F₂₀-TPP)Cl₂]-catalysed Intermolecular

C-H Amination of Hydrocarbons with Phosphoryl Azide (Table 3)

To an oven-dried Schlenk flask with a rubber seal was added bis(2,2,2-trichloroethyl) phosphorazidate (77 mg, 0.2 mmol), $[Ru^{IV}(F_{20}-TPP)Cl_2]$ (4.2 mg, 2 mol %) and 100 mg of 4Å molecular sieve. The flask was evacuated and backfilled with argon three times. Then the substrate (4 mmol, 20 equiv.) and freshly distilled DCE (3 mL) were added via syringe. The mixture was stirred at reflux for 12h. Upon completion of the reaction, the reaction mixture was allowed to cool to room temperature and purified on a silica gel column with DCM/acetone (50:1, v/v) as eluent to give the pure product.

VII. General Procedure for the $[Ru^{IV}(F_{20}-TPP)Cl_2]$ -catalysed Intramolecular C-H Amination of Phosphorazidates (Scheme 1)

Phosphorazidate (0.2 mmol), $[Ru(F_{20}TPP)Cl_2]$ (0.2 mol %) and 100 mg of 4Å molecular

sieve were added into an oven-dried Schlenk flask which was subsequently evacuated and backfilled with argon three times. Then freshly distilled DCE (3 mL)was added via syringe into the flask. The reaction mixture was stirred at reflux for 12 h until the substrate was completely converted. Subsequently, the reaction mixture was filtered and concentrated by rotary evaporator to give corresponding product. Product **5a** and **5b** were purified on a short silica gel column with DCM as eluent.

VIII. Procedure for the Study of Deuterium Kinetic Isotope Effects



To an oven-dried Schlenk flask was added 77 mg (1 equiv.) of **2e**, 4.2 mg (2 mol %) of $[Ru^{IV}(TDCPP)Cl_2]$ and 100 mg of 4Å molecular sieve. The flask was sealed with a rubber septum, evacuated and backfilled with argon three times. Cyclohexane (2 mmol, 10 equiv.), cyclehexane- d_{12} (2 mmol, 10 equiv.) and 3 mL of freshly distilled DCE were added via syringe. The reaction mixture was stirred at reflux until azide **2e** was completely consumed. Then the reaction mixture was concentrated by rotary evaporator. The residue was purified by column chromatography (silica gel, hexane: EA = 3:1, v/v) to afford a mixture of **3e** and **3e**- d_{11} (N-D is liable to undergo H-D exchange). The value of k_H/k_D was determined according to the ¹H NMR spectrum of the product.

IX. Characterizations of Products

Bis(2,2,2-trichloroethyl) cyclohexylphosphoramidate 3e



¹H NMR (CDCl₃, 400MHz): δ 4.62-4.53 (m, 4H), 3.19-3.13 (m, 1H), 2.98 (t, 1H, J = 10.8Hz), 2.02-1.99 (m, 2H), 1.74-1.72 (m, 1H), 1.60-1.56 (m, 1H), 1.36-1.13 (m, 6H); ¹³C NMR (CDCl₃, 100MHz): δ 95.3, 95.2, 76.5, 76.4, 51.3, 35.6, 35.6, 25.3, 25.0; ³¹P NMR (CDCl₃, 162MHz): δ 6.0.

HRMS(EI) m/z Calcd for $C_{10}H_{16}C_{16}NO_3P[M]^+$ 440.8969, found 440.9071.

Bis(2,2,2-trichloroethyl) cyclopentylphosphoramidate 3f



¹H NMR (CDCl₃, 300MHz): δ 4.64-4.53 (m, 4H), 3.74-3.64 (m, 1H), 2.93 (t, 1H, J = 10.3Hz), 2.02-1.95 (m, 2H), 1.73-1.68 (m, 2H), 1.59-1.52 (m, 2H), 1.50-1.43 (m, 2H); ¹³C NMR (CDCl₃, 75MHz): δ 95.3, 95.2, 76.5, 76.4, 53.9, 35.0, 34.9, 23.3; ³¹P NMR (CDCl₃, 162MHz): δ 6.1.

HRMS(EI) m/z Calcd for $C_9H_{14}C_{16}NO_3P [M]^+$ 426.8813, found 426.8814.

Bis(2,2,2-trichloroethyl) cyclooctylphosphoramidate 3g



¹H NMR (CDCl₃, 400MHz): δ 4.62-4.52 (m, 4H), 3.49-3.39 (m, 1H), 3.19 (t, 1H, J = 11.2Hz), 1.97-1.91 (m, 2H), 1.66-1.52 (m, 12H); ¹³C NMR (CDCl₃, 75MHz): δ 95.3, 95.2, 76.4, 76.4, 52.3, 34.3, 34.3, 27.3, 25.4, 23.4; ³¹P NMR (CDCl₃, 162MHz): δ 5.7.

HRMS(EI) m/z Calcd for $C_{12}H_{20}C_{16}NO_3P$ [M]⁺ 468.9282, found 468.9281.

Bis(2,2,2-trichloroethyl) (1-phenylethyl)phosphoramidate 3h



¹H NMR (CDCl₃, 400MHz): δ 7.35-7.34 (m,4H), 7.28-7.24 (m, 1H), 4.59-4.46 (m, 4H), 4.26-4.22 (dd, 1H, *J* = 11.0, 5.2Hz), 3.75 (t, 1H, *J* = 10.6Hz), 1.56 (d, 3H, *J* = 6.8Hz); ¹³C NMR (CDCl₃, 100MHz): δ 144.2(d, *J* = 4.8Hz), 128.8, 127.6, 126.0, 95.2 (d, *J* = 12.0Hz), 95.0(d, *J* = 12.0Hz), 76.4 (d, *J* = 4.3Hz), 76.2 (d, *J* = 3.8Hz), 52.0, 24.9 (d, *J* = 6.6Hz); ³¹P NMR (CDCl₃, 162MHz): δ 5.1.

HRMS(EI) m/z Calcd for $C_{12}H_{14}C_{16}NO_3P[M]^+$ 462.8813, found 462.8809.

Bis(2,2,2-trichloroethyl) (1-(4-methoxyphenyl)ethyl)phosphoramidate 3i



¹H NMR (CDCl₃, 500MHz): δ 7.27 (d, 2H, J = 8.5Hz), 6.87 (d, 2H, J = 8.4Hz), 4.58-4.47 (m, 4H), 4.31 (dd, 1H, J = 11.0, 5.3Hz), 3.79 (s, 3H), 3.42 (t, 1H, J = 10.4Hz), 1.55 (d, 3H, J = 6.8Hz); ¹³C NMR (CDCl₃, 125MHz): δ 159.1, 136.2 (d, J = 5.2Hz), 127.2, 114.2, 95.3, 95.2, 76.5 (d, J = 4.1Hz), 76.3 (d, J = 3.9Hz), 55.4, 51.4, 24.8 (d, J = 6.3Hz); ³¹P NMR (CDCl₃, 162MHz): δ 5.5.

HRMS(ESI) m/z Calcd for C₁₃H₁₇C₁₆NO₄P [M+H]⁺ 493.8997, found 493.9019.

Bis(2,2,2-trichloroethyl) (1,2,3,4-tetrahydronaphthalen-1-yl)phosphoramidate 3j



¹H NMR (CDCl₃, 400MHz): δ 7.54-7.52 (m, 1H), 7.25-7.17 (m, 2H), 7.09-7.07 (m, 1H), 4.69-4.61 (m, 4H), 4.54-4.52 (m, 1H), 3.29 (t, 1H, J = 11.2Hz), 2.81-2.74 (m, 2H), 2.15-2.12 (m, 1H), 1.92-1.82 (m, 3H); ¹³C NMR (CDCl₃, 100MHz): δ 137.2 (d, J = 2.7Hz), 137.1, 129.1, 128.7, 127.5, 126.3, 95.1, 95.0, 76.5, 76.4, 50.4, 32.4 (d, J = 1.4Hz), 29.0, 19.5; ³¹P NMR (CDCl₃, 162MHz): δ 5.6.

HRMS(EI) m/z Calcd for $C_{14}H_{16}C_{16}NO_3P[M]^+$ 488.8969, found 488.8960.

Bis(2,2,2-trichloroethyl) (2,3-dihydro-1H-inden-1-yl)phosphoramidate 3k



¹H NMR (CDCl₃, 400MHz): δ 7.47-7.45 (m, 1H), 7.26-7.23 (m, 3H), 4.92-4.83 (m, 1H), 4.69-4.61 (m, 4H), 3.19 (t, 1H, J = 11.6Hz), 3.01-2.94 (m, 1H), 2.87-2.79 (m, 1H), 2.70-2.63 (m, 1H), 1.94-1.84 (m, 1H); ¹³C NMR (CDCl₃, 100MHz): δ 143.5 (d, J = 7.9Hz), 142.9, 128.3, 127.0, 125.0, 124.1, 95.2, 95.1, 76.6, 76.6, 57.4, 36.5 (d, J = 3.3Hz), 30.0; ³¹P NMR (CDCl₃, 162MHz): δ 5.9.

HRMS(EI) m/z Calcd for $C_{13}H_{14}C_{16}NO_3P[M]^+$ 474.8813, found 474.8809.

Bis(2,2,2-trichloroethyl) benzhydrylphosphoramidate 31



¹H NMR (CDCl₃, 400MHz): δ 7.35-7.25 (m, 10H), 5.61 (t, 1H, J = 9.8Hz), 4.53 (dd, 2H, J = 11.0, 6.5Hz), 4.32 (dd, 2H, J = 11.0, 5.3Hz), 4.15 (dd, 1H, J = 12.2, 9.9 Hz); ¹³C NMR (CDCl₃, 100MHz): δ 142.3, 142.2, 128.8, 127.8, 127.3, 95.1, 94.9, 76.3, 76.3, 59.6; ³¹P NMR (CDCl₃, 162MHz): δ 4.6.

HRMS(ESI) m/z Calcd for $C_{17}H_{17}C_{16}NO_3P [M+H]^+ 525.9048$, found 525.9195.

Bis(2,2,2-trichloroethyl) benzylphosphoramidate 3m



¹H NMR (CDCl₃, 400MHz): δ 7.36-7.35 (m, 4H), 7.31-7.28 (m, 1H), 4.63-4.59 (m, 2H), 4.56-4.51 (m, 2H), 4.26 (d, 1H, J = 7.8Hz), 4.24 (d, 1H, J = 7Hz), 3.3 (m, 1H); ¹³C NMR (CDCl₃, 75MHz): δ 138.7 (d, J = 6.2Hz), 128.9, 127.9, 127.6, 95.2, 95.0, 76.5, 76.5, 45.7; ³¹P NMR (CDCl₃, 162MHz): δ 6.2.

HRMS(EI) m/z Calcd for $C_{11}H_{12}C_{16}NO_3P[M]^+$ 448.8656, found 448.8654.

Bis(2,2,2-trichloroethyl) 3,5-dimethylbenzylphosphoramidate 3n



¹H NMR (CDCl₃, 400MHz): δ 6.97 (s, 2H), 6.92 (s, 1H), 4.62-4.58 (m, 2H), 4.55-4.51 (m, 2H), 4.17 (d, 1H, J = 6.8Hz), 4.14 (d, 1H, J = 6.8Hz), 3.40-3.33 (m, 1H), 2.30 (s, 6H); ¹³C NMR (CDCl₃, 100MHz): δ 138.6 (d, J = 5.9Hz), 138.5, 129.5, 125.4, 95.2, 95.1, 76.5, 76.4, 45.6, 21.3; ³¹P NMR (CDCl₃, 162MHz): δ 6.4.

HRMS(ESI) m/z Calcd for $C_{13}H_{17}C_{16}NO_3P [M+H]^+ 477.9048$, found 477.9086.

Bis(2,2,2-trichloroethyl) (naphthalen-2-ylmethyl)phosphoramidate 30



¹H NMR (CDCl₃, 500MHz): δ 7.83-7.79 (m, 4H), 7.50-7.46 (m, 3H), 4.63-4.53 (m, 4H), 4.39 (dd, 2H, *J* = 11.2, 7.0Hz), 3.70-3.64 (m, 1H); ¹³C NMR (CDCl₃, 125MHz): δ 136.0 (d, *J* = 5.9Hz), 133.4, 132.9, 128.7, 127.9, 127.8, 126.5, 126.3, 126.2, 125.5, 95.2. 95.1. 76.6, 76.5. 45.8; ³¹P NMR (CDCl₃, 162MHz): δ 6.0.

HRMS(ESI) m/z Calcd for C₁₅H₁₅C₁₆NO₃P [M+H]⁺ 499.8891, found 499.8882.

Bis(2,2,2-trichloroethyl) cyclohex-2-en-1-ylphosphoramidate 3p



¹H NMR (CDCl₃, 400MHz): δ 5.85-5.80 (m, 1H), 5.70-5.67 (m, 1H), 4.63-4.55 (m, 4H), 3.85 (br, 1H), 3.10 (t, 1H, J = 11.6Hz), 2.02-1.96 (m, 3H), 1.71-1.59 (m, 3H); ¹³C NMR (CDCl₃, 100MHz): δ 130.8, 129.1, 129.0, 95.3, 95.1, 76.5, 76.4, 47.6, 31.8 (d, J = 4.8Hz), 24.7, 19.7; ³¹P NMR (CDCl₃, 162MHz): δ 5.9

HRMS(EI) m/z Calcd for $C_{10}H_{14}Cl_6NO_3P$ [M]⁺ 438.8813, found 438.8801.

Bis(2,2,2-trichloroethyl) hexan-2-ylphosphoramidate 3q



¹H NMR (CDCl₃, 500MHz): δ 4.63-4.53 (m, 4H), 3.40-3.30 (m, 1H), 2.92 (t, 1H, J = 11.0Hz), 1.54-1.41 (m, 2H), 1.41-1.28 (m, 4H), 1.23 (d, 3H, J = 6.5Hz), 0.90 (t, 3H, J = 6.9Hz); ¹³C

NMR (CDCl₃, 125MHz): δ 95.3, 95.2, 76.5 (d, *J* = 4.1Hz), 76.4 (d, *J* = 4.3Hz), 48.7, 38.7 (d, *J* = 6.7Hz), 28.2, 23.3 (d, *J* = 3.9Hz), 22.6, 14.2; ³¹P NMR (CDCl₃, 162MHz): δ 6.1.

HRMS(ESI) m/z Calcd for $C_{10}H_{19}C_{16}NO_3P [M+H]^+ 443.9204$, found 443.9131.

Bis(2,2,2-trichloroethyl) hexan-2-ylphosphoramidate 3q + Bis(2,2,2-trichloroethyl) hexan-3-ylphosphoramidate 3s



¹H NMR (CDCl₃, 500MHz): δ 4.65-4.53 (m, C7–H + C7'–H), 3.40-3.32 (m, C2–H), 3.25-3.15 (m, C3'–H), 2.77-2.65 (m, NH, **3q** + **3s**), 1.60-1.56 (m, C2'–H), 1.53-1.41 (m, C3–H + C4'–H), 1.40-1.27 (m, C4–H + C5–H + C5'–H), 1.23 (d, *J* = 6.5Hz, C1-H), 0.97-0.88 (m, C6–H + C1'–H + C6'–H); ¹³C NMR (CDCl₃, 125MHz): δ 95.3, 95.2, 76.5 (d, *J* = 4.1Hz), 76.4 (d, *J* = 4.4Hz), 54.0, 48.8, 38.7 (d, *J* = 6.7Hz), 38.5 (d, *J* = 5.4Hz), 29.3 (d, *J* = 4.9Hz), 28.3, 23.4 (d, *J* = 4.0Hz), 22.7, 19.0, 14.2, 10.0; ³¹P NMR (CDCl₃, 162MHz): δ 6.4, 6.1.

HRMS(ESI) m/z Calcd for $C_{10}H_{19}Cl_6NO_3P [M+H]^+ 443.9204$, found 443.9193.

2-Phenoxy-4-phenyl-1,3,2-oxazaphosphinane 2-oxide 5a



¹H NMR (CDCl₃, 400MHz): δ 7.31-7.16 (m, 10H), 4.69 (m, 1H), 4.49-4.42 (m, 2H), 3.96 (m, 1H), 2.19(m, 2H); ¹³C NMR (CDCl₃, 100MHz): δ 151.3 (d, J = 7.2Hz), 142.8 (d, J = 3.9Hz), 129.7, 128.8, 127.9, 126.1, 124.6, 120.4 (d, J = 5.1Hz), 67.6 (d, J = 6.6Hz), 56.6, 33.3(d, J = 10.5Hz); ³¹P NMR (CDCl₃, 162MHz): δ -1.7.

HRMS(ESI) m/z Calcd for $C_{15}H_{17}NO_3P [M+H]^+ 290.0946$, found 290.0949.

4-Methyl-2-phenoxy-1,3,2-oxazaphosphinane 2-oxide 5b



¹H NMR (CDCl₃, 400MHz): δ 7.34-7.30 (t, 2H), 7.24 (t, 2H, J = 8.0Hz), 7.14 (t, 1H, J = 7.2Hz), 4.52-4.41 (m, 1H), 4.41-4.32 (m, 1H), 3.73-3.63 (m, 1H), 3.44 (br, 1H), 2.06-2.03 (m, 1H), 1.74-1.66 (m, 1H), 1.24 (d, 3H, J = 6.5Hz); ¹³C NMR (CDCl₃, 100MHz): δ 151.3 (d, J = 7.4Hz), 129.7, 124.6, 120.4 (d, J = 4.9Hz), 67.1 (d, J = 6.9Hz), 48.1 (d, J = 2.3Hz), 31.8 (d, J = 9.3Hz), 23.3 (d, J = 2.0Hz); ³¹P NMR (CDCl₃, 162MHz): δ -1.26.

HRMS(ESI) m/z Calcd for $C_{10}H_{15}NO_3P [M+H]^+ 228.0790$, found 228.0812.

4,4-dimethyl-2-phenoxy-1,3,2-oxazaphospholidine 2-oxide 5c



¹H NMR (CDCl₃, 500MHz): δ 7.35-7.31 (t, 2H, J = 7.3Hz), 7.21-7.15 (m, 3H), 4.01 (dd, 1H, J = 14.5, 8.6Hz), 3.90 (d, 1H, J = 15.7Hz), 3.72 (t, 1H, J = 8.6Hz), 1.39 (s, 3H), 1.12 (s, 3H); ¹³C NMR (CDCl₃, 125MHz): δ 151.0 (d, J = 8.1Hz), 129.6, 125.1, 121.2 (d, J = 4.3Hz), 77.9 (d, J = 1.9Hz), 56.7 (d, J = 9.7Hz), 28.8 (d, J = 3.6Hz), 28.0 (d, J = 5.7Hz); ³¹P NMR (CDCl₃, 162MHz): δ 19.6.

HRMS(ESI) m/z Calcd for $C_{10}H_{15}NO_3P [M+H]^+ 228.0790$, found 228.0812.

2-phenoxy-4-phenyl-1,3,2-oxazaphospholidine 2-oxide 5d



¹H NMR (CDCl₃, 500MHz): δ 7.38-7.11 (m, 10H), 4.89 (t, 1H, J = 8.1Hz), 4.55-4.47 (m, 1H), 4.16 (d, J = 14.3Hz), 3.80 (td, 1H, J = 9.1, 2.1Hz); ¹³C NMR (CDCl₃, 125MHz): δ 151.1 (d, J

= 8.3), 139.0 (d, J = 9.6Hz), 129.8, 128.9, 128.6, 126.4, 125.3, 121.2 (d, J = 4.2Hz), 73.0, 57.8 (d, J =11.0Hz); ³¹P NMR (CDCl₃, 162MHz): δ 19.8.

HRMS(ESI) m/z Calcd for $C_{14}H_{15}NO_3P [M+H]^+ 276.0790$, found 276.0774.

Electronic Supplementary Material (ESI) for Chemical Communications This journal is C The Royal Society of Chemistry 2013

NMR Spectra

$[Ru^{IV}(F_{20}\text{-}TPP)Cl_2]$







Butyl phenyl phosphorazidate 4b







Phenethyl phenyl phosphorazidate 4d



Bis(2,2,2-trichloroethyl) cyclohexylphosphoramidate 3e





Bis(2,2,2-trichloroethyl) cyclopentylphosphoramidate 3f















Bis(2,2,2-trichloroethyl) (1,2,3,4-tetrahydronaphthalen-1-yl)phosphoramidate 3j



Bis(2,2,2-trichloroethyl) (2,3-dihydro-1H-inden-1-yl)phosphoramidate 3k









and the second sec





Bis(2,2,2-trichloroethyl) 3,5-dimethylbenzylphosphoramidate 3n



Bis(2,2,2-trichloroethyl) (naphthalen-2-ylmethyl)phosphoramidate 30



Bis(2,2,2-trichloroethyl) cyclohex-2-en-1-ylphosphoramidate 3p





Mixture of 3q and 3s



2-Phenoxy-4-phenyl-1,3,2-oxazaphosphinane 2-oxide 5a



4-Methyl-2-phenoxy-1,3,2-oxazaphosphinane 2-oxide 5b





4,4-dimethyl-2-phenoxy-1,3,2-oxazaphospholidine 2-oxide 5c





Study of Deuterium Kinetic Isotope Effects

